Eam Investors, LLC Sarepta Therapeutics, Inc. Transaction History

Eam Investors, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$117.53 - $155.99 $1.42 Million - $1.88 Million	12,075 Added 142.21%	20,566 $2.83 Million
Q4 2022 Feb 14, 2023	SELL	$100.86 - $132.13 $423,410 - $554,681	-4,198 Reduced 33.08%	8,491 $1.1 Million
Q3 2022 Nov 14, 2022	BUY	$75.71 - $119.24 $960,684 - $1.51 Million	12,689 New	12,689 $1.4 Million
Q1 2019 May 13, 2019	SELL	$106.67 - $151.68 $930,375 - $1.32 Million	-8,722 Closed	0 $0
Q4 2018 Feb 13, 2019	SELL	$97.32 - $148.76 $588,202 - $899,105	-6,044 Reduced 40.93%	8,722 $952,000
Q3 2018 Nov 08, 2018	SELL	$115.31 - $161.51 $1.26 Million - $1.76 Million	-10,926 Reduced 42.53%	14,766 $2.39 Million
Q2 2018 Aug 03, 2018	SELL	$71.74 - $153.69 $1.03 Million - $2.2 Million	-14,288 Reduced 35.74%	25,692 $3.4 Million
Q1 2018 May 14, 2018	SELL	$54.02 - $82.27 $536,958 - $817,763	-9,940 Reduced 19.91%	39,980 $2.96 Million
Q4 2017 Feb 12, 2018	SELL	$47.64 - $56.75 $535,235 - $637,586	-11,235 Reduced 18.37%	49,920 $2.78 Million
Q3 2017 Nov 08, 2017	BUY	$35.73 - $47.15 $2.19 Million - $2.88 Million	61,155	61,155 $2.77 Million

529

84.2M

2.06M

1.52M

Ticker SRPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,567,904
Market Cap $10.4B
Description
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...

Get notified when there are updates to the investment portfolio of Eam Investors, LLC, based on Form 13F filings with the SEC.

Stay updated on Eam Investors, LLC with notifications on news.